Linezolid-d8

Linezolid-d8 Suppliers list
Company Name: Quality Control Solutions Ltd.  
Tel: 0755-66853366 13670046396
Email: orders@qcsrm.com
Company Name: Pushan Industry (Shaanxi) Co., Ltd.  
Tel: 029-81310890 18165209495
Email: 2929288192@qq.com
Company Name: Shanghai YuZn Pharm. Technology Co.,Ltd.  
Tel: 15921286451; 15921286451
Email: 2010681527@qq.com
Company Name: Shandong Dayou Pharmaceutical Research and Development Co., Ltd.  
Tel: hanfangpharma@126.com 15165037910
Email: hanfangpharma@126.com
Company Name: Changzhou Xianglong Pharmaceutical Technology Co., Ltd.,  
Tel: 18915873328 18915873328
Email: sales@xianglongpharm.com
Linezolid-d8 Basic information
Product Name:Linezolid-d8
Synonyms:Linezolid-d8;Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl-2,2,3,3,5,5,6,6-d8)phenyl]-2-oxo-5-oxazolidinyl]methyl]-
CAS:1032182-14-1
MF:C16H12D8FN3O4
MW:345.4
EINECS:
Product Categories:
Mol File:1032182-14-1.mol
Linezolid-d8 Structure
Linezolid-d8 Chemical Properties
Safety Information
WGK Germany WGK 2
Storage Class3 - Flammable liquids
Hazard ClassificationsAcute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral
Flam. Liq. 2
STOT SE 1
MSDS Information
Linezolid-d8 Usage And Synthesis
UsesPNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics[1][2][3].
References[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. DOI:10.2165/00003495-200059040-00007
[3] Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. DOI:10.1016/j.clinthera.2010.01.019
[4] Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. DOI:10.2165/00003495-200161040-00008
[5] He MZ, Jiang YW, Cai C. Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. PMID:22883997
[6] Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G. Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice. Antimicrob Agents Chemother. 2012 Jul 30. DOI:10.1128/AAC.01080-12
Linezolid-d8 Preparation Products And Raw materials
Tag:Linezolid-d8(1032182-14-1) Related Product Information